Progentec Diagnostics, a precision diagnostics and digital health company focused on improving care for autoimmune diseases, has raised $5 million in Series A funding to accelerate commercialization of its lupus diagnostic technologies and expand development of digital health solutions. The financing supports the company’s efforts to bring advanced biomarker testing and remote monitoring tools to patients and healthcare providers managing complex autoimmune conditions.

The Series A round was led by Plains Venture Partners, with participation from Oklahoma Seed Capital Fund and Oklahoma Angel Capital Fund II, managed by i2E. Additional investors included NMC Health, OCA Ventures, Stanford University, Oklahoma Medical Research Foundation, Mayo Clinic, and Burns & Stowers Investments. The funding was announced as Progentec prepared to commercialize its aiSLE DX Lupus Flare Prediction Test, develop its lupus classification and diagnosis test, and expand research into digital biomarkers.

Founded to address significant gaps in autoimmune disease diagnosis and management, Progentec Diagnostics develops technologies designed to help physicians better understand disease activity and predict changes in patient health. The company’s primary focus has been systemic lupus erythematosus (SLE), a chronic autoimmune disease in which the immune system attacks healthy tissues and can cause periods of worsening symptoms known as flares.

Progentec’s technology platform combines biomarker-based laboratory testing with digital health tools to provide more proactive disease management. Its aiSLE DX platform uses blood-based biomarkers to help identify lupus disease activity and assess the risk of future flares. The company aims to give clinicians additional information to make more informed treatment decisions while helping patients better manage their conditions.

The Series A financing followed earlier investment rounds that supported the development of Progentec’s diagnostic platform. The company previously completed a $1.25 million financing round led by i2E, with participation from OCA Ventures and Mayo Clinic Ventures. Those funds were used to advance the company’s technology for predicting lupus flares and move its diagnostic tools closer to commercialization.

Progentec’s approach builds on scientific research developed through collaboration with the Oklahoma Medical Research Foundation. The company has worked to translate immune-based discoveries into commercially available diagnostic solutions that can support physicians treating autoimmune disorders. The company’s leadership has emphasized the importance of combining laboratory diagnostics with digital monitoring to create a more comprehensive approach to chronic disease management.

The newly raised capital has enabled Progentec to continue advancing its diagnostic pipeline and expand research into digital biomarkers. The company has also pursued collaborations with healthcare organizations to improve access to its testing technologies. Through partnerships with organizations such as Mayo Clinic Laboratories, Progentec has worked to make its lupus biomarker tests available to healthcare providers.

In addition to lupus diagnostics, Progentec has explored broader applications for its technology in autoimmune diseases, including multiple sclerosis and other chronic immune-related conditions. The company’s long-term vision is to create a platform that combines predictive diagnostics, digital health technologies, and personalized care management tools.

Investor participation from organizations including Plains Venture Partners, OCA Ventures, and i2E reflects growing interest in healthcare companies developing precision medicine solutions. As healthcare systems increasingly focus on earlier diagnosis and personalized treatment approaches, diagnostic companies using biomarkers and digital technologies are gaining attention for their potential to improve patient outcomes.

The funding also comes as autoimmune diseases continue to represent a major healthcare challenge. Many autoimmune conditions require long-term management and involve complex treatment decisions, making accurate monitoring and early intervention important components of patient care. Progentec’s diagnostic technologies are designed to help close gaps in current disease monitoring methods by providing physicians with additional clinical insights.

With its $5 million Series A financing, Progentec Diagnostics is positioned to continue expanding its precision medicine platform and advancing its mission of improving outcomes for people living with autoimmune diseases. By combining biomarker testing, artificial intelligence, and digital health tools, the company aims to provide healthcare providers with new ways to detect disease activity, predict complications, and deliver more personalized care.

Related Articles